Indications for Carbon Ion Therapy – Head and Neck Neuro-Oncology Tumors
Indications for Carbon Ion Therapy – Head and Neck Neuro-Oncology Tumors
Heavy ion therapy (including carbon ion therapy), owing to its unique radiophysical properties (such as the Bragg peak) and biological advantages (such as induction of DNA double-strand breaks), demonstrates favorable efficacy against solid tumors throughout the body. It is particularly advantageous for tumors that are less sensitive to conventional photon radiotherapy, hypoxic tumors, recurrent tumors, tumors requiring re-irradiation, and tumors located in certain anatomically challenging or special sites.

Based on clinical research evidence, the primary indications for carbon ion therapy in head and neck neuro-oncology (including but not limited to the following tumor types) are:
Here’s the professional English translation of your structured list on indications for carbon ion therapy in neuro-oncology and head & neck tumors, formatted for clarity and academic precision:
1. Cranial Nerve Tumors (Central Nervous System)
(1) High-grade gliomas
(2) Meningiomas
(3) Skull base and spinal tumors (chordomas and chondrosarcomas)
(4) Intracranial metastases
2. Head and Neck Tumors
(1) Mucosal malignant melanoma
(2) Adenoid cystic carcinoma
(3) Intraorbital and intraocular tumors (uveal melanoma)
(4) Nasopharyngeal carcinoma, including:
•Primary definitive radiotherapy
•Re-irradiation for recurrent tumors
(5) Other head and neck tumors, including:
•Sinonasal tumors
•Salivary gland tumors
•Oral cavity cancers (and others)•Primary definitive radiotherapy•Re-irradiation for recurrent tumors
The following case illustrates an example of definitive heavy ion radiotherapy for a patient with laryngeal cancer.

As more heavy ion therapy centers become operational in China, the indications for heavy ion radiotherapy will be further standardized and expanded.



Hu Tingzhao, Associate Chief Physician in Radiation Oncology
•Director of the Fifth Department of Radiotherapy (Head and Neck Tumor Radiotherapy), Wuwei Cancer Hospital, Gansu Province
•Member of the Chinese Anti-Cancer Association
•Member of the Gansu Provincial Radiotherapy Committee
•Council Member of the Third Council of the Western Radiotherapy Association
•Member of the Particle Therapy Branch, China Medical Equipment Association
Education:
Graduated from the Clinical Medicine Department of Lanzhou University in 2005. With 18 years of experience in tumor radiotherapy, he has completed advanced training in radiation oncology at Sichuan Cancer Hospital, Fukuoka Teishinkai Hospital in Japan, Shanghai Proton and Heavy Ion Center, and Sun Yat-sen University Cancer Center in Guangzhou.
Specialties:
1.Expertise in the comprehensive treatment (including radiotherapy, chemotherapy, targeted therapy, etc.) of various common malignant tumors such as head and neck tumors, gliomas, lymphomas, and chordomas.
2.Precision radiotherapy: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), image-guided radiotherapy (IGRT), carbon ion radiotherapy (CIRT). Extensive experience in radiotherapy planning, protection of normal organ function, and mitigation and management of radiotherapy side effects.
Research & Publications:
Published over ten professional papers, authored one monograph, holds one utility model patent, presided over two municipal-level scientific research projects in Wuwei, participated in the formulation of standard procedures for carbon ion radiotherapy, and has been awarded the title of “Advanced Worker” by the hospital multiple times.
Fifth Department of Radiotherapy (Head and Neck Tumor Radiotherapy):
A specialized ward integrating clinical care, research, and teaching.
Main Admitted Diseases:
Meningioma, pituitary tumor, acoustic neuroma, glioma, intracranial tumors, nasopharyngeal carcinoma, oral cancer, ocular tumors, laryngeal cancer, hard palate cancer, hypopharyngeal cancer, chordoma, lymphomas of various body parts.
Advantageous Diseases for Heavy Ion Therapy:
Malignant melanoma of the head and neck, sarcoma of the head and neck, adenoid cystic carcinoma, recurrent head and neck cancer, skull base chordoma, chondrosarcoma, glioma.

Yin Chaocheng
Deputy Director of the Fifth Department of Radiotherapy,
Member of the Communist Party of China, Associate Chief Physician in Radiation Oncology
Former Director of the Department of Radiotherapy, Affiliated Hospital of Xiangnan University, Hunan Province
Standing Committee Member, Oncology Professional Committee, Chenzhou Medical Association
Committee Member, Tumor Radiotherapy and Radiotherapy Immunology Professional Committee, Hunan International Medical Exchange Promotion Association
Committee Member, Clinical Nutrition Professional Committee, Hunan Medical Education Science and Technology Society

